Ontology type: schema:ScholarlyArticle
2021-08-02
AUTHORSKazuhito Suzuki, Kaichi Nishiwaki, Riku Nagao, Mitsuji Katori, Ryoko Fukushima, Daiki Hattori, Hidekazu Masuoka, Shingo Yano
ABSTRACTMinimal residual disease (MRD) is a surrogate marker for survival in multiple myeloma (MM), while the lymphocyte-to-monocyte ratio (LMR) is a prognostic factor associated with the patients’ immunological status. We retrospectively evaluated the clinical impact of MRD negativity and LMR. MRD was analyzed by multicolor flowcytometry (threshold, 1 × 10–5). Fifty-eight patients (median age 70 years) who achieved complete response were included in this study. Twenty-two patients received autologous stem cell transplantation, 14 received daratumumab-based chemotherapy, and 22 received another treatment. Forty-one (70.7%) patients achieved MRD negativity. Over the median follow-up time of 15.1 months, PFS in MRD-negative patients was significantly longer than in MRD-positive patients (P = 0.020). In addition, a high LMR at MRD assessment was associated with MRD negativity (P = 0.019) and long PFS (P = 0.009). Finally, neither MRD negativity nor high LMR at MRD assessment was associated with significantly shorter PFS compared with MRD positivity or low LMR (P = 0.002). In conclusion, high LMR was associated with MRD negativity and can be used as a predictor of long PFS. Change of treatment strategy might be essential for patients with MRD positivity and high LMR at MRD assessment due to their short PFS. More... »
PAGES599-607
http://scigraph.springernature.com/pub.10.1007/s12185-021-03201-y
DOIhttp://dx.doi.org/10.1007/s12185-021-03201-y
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1140125322
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/34339005
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Clinical Sciences",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged, 80 and over",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Biomarkers",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Biomarkers, Tumor",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Disease Management",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Disease Susceptibility",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Female",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Leukocyte Count",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Lymphocyte Count",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Lymphocytes",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Male",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Middle Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Monocytes",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Multiple Myeloma",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Neoplasm, Residual",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Prognosis",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Retrospective Studies",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "The Jikei University School of Medicine, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/grid.411898.d",
"name": [
"Division of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University Kashiwa Hospital, 163-1 Kashiwa-shita, 277-8567, Kashiwa, Chiba, Japan",
"The Jikei University School of Medicine, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Suzuki",
"givenName": "Kazuhito",
"id": "sg:person.01237063604.97",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01237063604.97"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "The Jikei University School of Medicine, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/grid.411898.d",
"name": [
"Division of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University Kashiwa Hospital, 163-1 Kashiwa-shita, 277-8567, Kashiwa, Chiba, Japan",
"The Jikei University School of Medicine, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Nishiwaki",
"givenName": "Kaichi",
"id": "sg:person.01016710710.32",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01016710710.32"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "The Jikei University School of Medicine, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/grid.411898.d",
"name": [
"Division of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University Kashiwa Hospital, 163-1 Kashiwa-shita, 277-8567, Kashiwa, Chiba, Japan",
"The Jikei University School of Medicine, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Nagao",
"givenName": "Riku",
"id": "sg:person.015357612447.65",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015357612447.65"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "The Jikei University School of Medicine, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/grid.411898.d",
"name": [
"Division of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University Kashiwa Hospital, 163-1 Kashiwa-shita, 277-8567, Kashiwa, Chiba, Japan",
"The Jikei University School of Medicine, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Katori",
"givenName": "Mitsuji",
"id": "sg:person.014735732441.34",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014735732441.34"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "The Jikei University School of Medicine, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/grid.411898.d",
"name": [
"Division of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University Kashiwa Hospital, 163-1 Kashiwa-shita, 277-8567, Kashiwa, Chiba, Japan",
"The Jikei University School of Medicine, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Fukushima",
"givenName": "Ryoko",
"id": "sg:person.011347513173.04",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011347513173.04"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "The Jikei University School of Medicine, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/grid.411898.d",
"name": [
"Division of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University Kashiwa Hospital, 163-1 Kashiwa-shita, 277-8567, Kashiwa, Chiba, Japan",
"The Jikei University School of Medicine, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Hattori",
"givenName": "Daiki",
"id": "sg:person.016103216547.04",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016103216547.04"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "The Jikei University School of Medicine, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/grid.411898.d",
"name": [
"Division of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University Kashiwa Hospital, 163-1 Kashiwa-shita, 277-8567, Kashiwa, Chiba, Japan",
"The Jikei University School of Medicine, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Masuoka",
"givenName": "Hidekazu",
"id": "sg:person.01065024110.36",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01065024110.36"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "The Jikei University School of Medicine, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/grid.411898.d",
"name": [
"The Jikei University School of Medicine, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Yano",
"givenName": "Shingo",
"id": "sg:person.01265010246.42",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01265010246.42"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1038/sj.bmt.1705373",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1047732682",
"https://doi.org/10.1038/sj.bmt.1705373"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s11899-021-00633-5",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1137751851",
"https://doi.org/10.1007/s11899-021-00633-5"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/leu.2010.320",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1024484528",
"https://doi.org/10.1038/leu.2010.320"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s12185-019-02615-z",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1112212201",
"https://doi.org/10.1007/s12185-019-02615-z"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/bcj.2017.60",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1090295330",
"https://doi.org/10.1038/bcj.2017.60"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/s41375-018-0163-4",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1104990592",
"https://doi.org/10.1038/s41375-018-0163-4"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/bmt.2012.244",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1028358194",
"https://doi.org/10.1038/bmt.2012.244"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/s41409-019-0681-3",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1121007421",
"https://doi.org/10.1038/s41409-019-0681-3"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/nri1886",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1004152575",
"https://doi.org/10.1038/nri1886"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/s41408-017-0019-6",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1099676148",
"https://doi.org/10.1038/s41408-017-0019-6"
],
"type": "CreativeWork"
}
],
"datePublished": "2021-08-02",
"datePublishedReg": "2021-08-02",
"description": "Minimal residual disease (MRD) is a surrogate marker for survival in multiple myeloma (MM), while the lymphocyte-to-monocyte ratio (LMR) is a prognostic factor associated with the patients\u2019 immunological status. We retrospectively evaluated the clinical impact of MRD negativity and LMR. MRD was analyzed by multicolor flowcytometry (threshold, 1\u2009\u00d7\u200910\u20135). Fifty-eight patients (median age 70\u00a0years) who achieved complete response were included in this study. Twenty-two patients received autologous stem cell transplantation, 14 received daratumumab-based chemotherapy, and 22 received another treatment. Forty-one (70.7%) patients achieved MRD negativity. Over the median follow-up time of 15.1\u00a0months, PFS in MRD-negative patients was significantly longer than in MRD-positive patients (P\u2009=\u20090.020). In addition, a high LMR at MRD assessment was associated with MRD negativity (P\u2009=\u20090.019) and long PFS (P\u2009=\u20090.009). Finally, neither MRD negativity nor high LMR at MRD assessment was associated with significantly shorter PFS compared with MRD positivity or low LMR (P\u2009=\u20090.002). In conclusion, high LMR was associated with MRD negativity and can be used as a predictor of long PFS. Change of treatment strategy might be essential for patients with MRD positivity and high LMR at MRD assessment due to their short PFS.",
"genre": "article",
"id": "sg:pub.10.1007/s12185-021-03201-y",
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1076985",
"issn": [
"0925-5710",
"1865-3774"
],
"name": "International Journal of Hematology",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "5",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "114"
}
],
"keywords": [
"minimal residual disease",
"MRD negativity",
"high LMR",
"MRD assessment",
"monocyte ratio",
"longer PFS",
"MRD positivity",
"shorter PFS",
"residual disease",
"multiple myeloma",
"immunological status",
"autologous stem cell transplantation",
"single-center retrospective analysis",
"negative minimal residual disease",
"patient's immunological status",
"MRD-negative patients",
"MRD-positive patients",
"stem cell transplantation",
"multiple myeloma patients",
"multicolor flowcytometry",
"median follow",
"prognostic factors",
"complete response",
"low LMR",
"myeloma patients",
"cell transplantation",
"surrogate marker",
"treatment strategies",
"clinical impact",
"clinical significance",
"retrospective analysis",
"patients",
"PFS",
"LMR",
"lymphocytes",
"disease",
"positivity",
"negativity",
"chemotherapy",
"myeloma",
"transplantation",
"assessment",
"follow",
"flowcytometry",
"months",
"survival",
"treatment",
"predictors",
"markers",
"conclusion",
"status",
"response",
"factors",
"significance",
"study",
"ratio",
"changes",
"addition",
"strategies",
"impact",
"time",
"analysis"
],
"name": "Clinical significance of the lymphocyte-to-monocyte ratio in multiple myeloma patients with negative minimal residual disease: a single-center retrospective analysis",
"pagination": "599-607",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1140125322"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s12185-021-03201-y"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"34339005"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s12185-021-03201-y",
"https://app.dimensions.ai/details/publication/pub.1140125322"
],
"sdDataset": "articles",
"sdDatePublished": "2022-08-04T17:09",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_914.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1007/s12185-021-03201-y"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12185-021-03201-y'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12185-021-03201-y'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12185-021-03201-y'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12185-021-03201-y'
This table displays all metadata directly associated to this object as RDF triples.
285 TRIPLES
21 PREDICATES
115 URIs
97 LITERALS
25 BLANK NODES